Revenue segments as reported by the company.

MedSurg and Neurotechnology

Orthopaedics and Spine

Orthopaedics

MedSurg

Neurotechnology and Spine

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research, development and engineering

Selling, general and administrative

Recall charges

Amortization of intangible assets

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Stryker

MAKO was a publicly traded medical device company based in Florida. On September 25, 2013, the Board of Directors of Mako Surgical accepted a deal to be acquired by Stryker for $1.65B. The deal closed in December 2013. The company manufactures and markets surgical robotic arm assistance platforms, most notably the RIO as well as orthopedic implants used by orthopedic surgeons for use in partial knee and total hip arthroplasty. They are known for their intellectual property of devices and have over 300 U.S. and foreign patents and patent applications.

MAKO Surgical Corp

Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Stryker (SYK) exceeds Q4 expectations, poised for growth in 2023

Stryker (SYK) delivered exceptional financial results in Q4 2022, surpassing expectations and demonstrating resilience amid challenges. The company is well-positioned for growth with a strong pipeline of products and a focus on margin expansion. Despite ongoing market complexities, Stryker remains optimistic about its future performance.

Stryker reports robust Q1 results and optimistic outlook for 2023

Stryker's strong Q1 performance driven by organic sales growth and increased EPS, with positive outlook for the full year.
Company recognized for workplace excellence, leading in robotics, and expecting growth in medical division.
Challenges include supply chain uncertainties, margin impacts, and market disruptions, but opportunities lie in stakeholder engagement and business expansion.
Overall, Stryker remains focused on innovation, debt reduction, and strategic acquisitions for future growth.

Stryker reports stellar Q2 results, eyes international growth opportunities

Stryker's Q2 performance reflects robust sales growth, margin improvement, and strategic acquisitions driving financial strength.
While facing challenges in the U.S. market and competitive landscapes, Stryker's focus on innovation and international growth presents promising opportunities.
The company's financial resilience, debt reduction strategy, and upcoming product launches position Stryker for sustained success and market expansion.
Overall, Stryker's strong performance, coupled with a focus on innovation and strategic growth initiatives, sets a positive trajectory for future success.

Stryker reports robust Q3 earnings, eyes international growth and M&A

Stryker's Q3 performance reflects strong sales growth and earnings increase, driven by key segments and product lines. Challenges include market competition and potential shifts in procedure trends, while opportunities exist in international expansion and strategic acquisitions.

Stryker exceeds $20B in sales, eyes continued growth and innovation

Stryker's Q4 performance showcased strong sales growth, margin expansion, and successful acquisitions, positioning the company for continued success.
While facing challenges in pricing and potential regulatory impacts, Stryker's focus on innovation and strategic growth initiatives presents promising opportunities.
The company's robust pipeline of innovative products and successful integration efforts highlight its resilience and potential for sustained growth.
With a solid financial foundation and strategic vision, Stryker is well-positioned to capitalize on market opportunities and drive future profitability.

Stryker reports strong Q1 growth, eyes international expansion opportunities

Stryker's Q1 2024 earnings call reflects strong performance, with double-digit organic sales growth and increased guidance for the full year.
The company's focus on innovation, successful acquisitions, and market recognition position it well for future growth and leadership in key segments.
While facing challenges like regulatory delays and market dependencies, Stryker remains optimistic about meeting targets and driving growth through new products and acquisitions.
Opportunities in international expansion, AI solutions, and continued market growth present avenues for sustained success and market leadership for Stryker.

Stryker reports robust Q2 earnings, raises 2024 outlook on acquisitions and margin expansion

Stryker's strong Q2 performance, strategic acquisitions, and focus on margin expansion position the company for continued growth. Despite challenges like foreign exchange rates and market softness in certain segments, Stryker's product strength, innovation pipeline, and international growth opportunities offer a positive outlook. With a commitment to driving margins and expanding its product portfolio, Stryker remains poised for sustained success in the medical technology industry.

Stryker reports robust Q3 performance with strong growth and strategic acquisitions

Stryker's Q3 showcased strong organic sales and EPS growth, driven by MedSurg and Neurotechnology segments.
Strategic acquisitions, record Mako installations, and operational efficiency improvements underpin performance.
Challenges in the ischemic stroke segment and competitor actions pose risks, while pricing trends and margin efficiencies are under scrutiny.
Opportunities lie in M&A expansion, growth in high-demand areas, and sustained market momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Stryker is a leading medical technology company with a diversified product portfolio that targets orthopedic surgery amongst other end markets. Stryker is currently reaping the rewards of a decade of heavy investment (R&D and M&A), with growth picking up and margins set to follow. Stryker's bright prospects are gradually being priced into the stock, with the company's revenue multiple expanding over the past decade.

Stryker: Rerating Higher

Portage, Michigan, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024 at Citigroup Headquarters, New York, New York.

Stryker to participate in Citi's 2024 Unplugged Medtech and Life Sciences Access Day

Superb quality often comes with a price, which is a lesson that I learned with Stryker. The medtech giant's net sales and adjusted diluted EPS both climbed at double-digit clips in Q4. Stryker earns a BBB+ credit rating from S&P on a stable outlook.

Stryker: A Dividend Growth Powerhouse I'd Like To Own

Boston Scientific

Shares of Stryker Corp. SYK, +7.67%, Boston Scientific Corp. BSX, +3.50% and other medical-technology companies jumped Wednesday as sustained demand for medical procedures brightened investors' outlook on the device makers.

Medical-device makers' stocks jump as procedures keep going strong

Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments and geographies. Operating and gross margins increased, with earnings and revenues beating estimates.

Stryker's (SYK) Q4 Earnings & Revenues Surpass Estimates

PORTAGE, Mich.--(BUSINESS WIRE)--Stryker launched Prophecy Footprint, an expansion of the Prophecy Surgical Planning system, offering surgical planning across the entire foot.

Stryker Expands Prophecy® Surgical Planning System to Include the New Footprint™, Offering Surgeons a Comprehensive View of the Foot and Ankle

Shares of Stryker, Boston Scientific jumped early Wednesday after healthy earnings beats and price target hikes from analysts.

Stryker, Boston Scientific Score Earnings Beats, Extend Breakouts

Abbott Labs

Intuitive Surgical

Johnson & Johnson

Med tech stocks have been a mixed bag of results the last two years, with most moving within established trading ranges. The impact of COVID and its effect on procedure volumes were slow to dissipate, and the growth outlook was uncertain, leaving the market for their stock without a solid catalyst to drive it despite many trading at value levels and paying healthy dividends.

4 med tech stocks with improving prognosis for 2024

Stryker Corporation (SYK) Q4 2023 Earnings Call Transcript

The headline numbers for Stryker (SYK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Stryker (SYK) Reports Q4 Earnings: What Key Metrics Have to Say

Stryker (SYK) came out with quarterly earnings of $3.46 per share, beating the Zacks Consensus Estimate of $3.27 per share. This compares to earnings of $3 per share a year ago.

Stryker (SYK) Surpasses Q4 Earnings and Revenue Estimates

Stryker Corp forecast 2024 profit above Wall Street estimates on Tuesday, banking on a post-pandemic pick-up in volume for certain surgical procedures at hospitals to drive sales for its medical and surgical devices.

Stryker forecasts strong 2024 as uptick in surgeries lift demand for devices

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Stryker (SYK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

Countdown to Stryker (SYK) Q4 Earnings: Wall Street Forecasts for Key Metrics

NVIDIA

UiPath

The robotics sector is on the brink of an extraordinary boom, with MarketsandMarkets projecting its value to skyrocket from $17.0 billion in 2023 to $32.5 billion by 2028. This steep ascent is just the beginning.

3 Robotics Stocks to Buy and Hold Forever: January 2024

With the expansion of Gamma4, Stryker (SYK) is looking forward to strengthening its nailing system and solidifying its position as a leading choice in Orthopedic procedures.

Stryker's (SYK) Gamma4 Expansion Set to Boost Fracture Healing

Stryker's (SYK) Blueprint Mixed Reality Guidance system aims to benefit shoulder arthroplasty surgeons by improving efficiency and minimizing errors.

Stryker's (SYK) New Tech Aims to Improve Surgeon's Efficiency

Eli Lilly

Eli Lilly and Stryker are reaching all-time highs and buy points at the same time.

Two Health Care Leaders Scale New Highs On Big Wins

Amgen

Here are three stocks in the health care sector that could provide further upside potential based on their improving technical characteristics.

Health care stocks are back in favor and these 3 names could lead the rally, according to the charts

KALAMAZOO, Mich.--(BUSINESS WIRE)--Stryker announced that the first shoulder arthroplasty surgeries using Blueprint® Mixed Reality Guidance have been successfully completed.

First Shoulder Arthroplasty Surgeries Using Stryker's Blueprint® Mixed Reality Guidance System Completed at Mayo Clinic in Minnesota and at St. Joseph's Health Care London in Canada

Rockwell Automation

One very promising and innovative area of technology is robotics. Finding the best robotics stocks is not only a stroke of luck for savvy investors looking to exploit this highly-growing industry.

The 3 Best Robotics Stocks to Buy in January 2024

Portage, Michigan, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that it surpassed $20 billion in annual sales for the first time in its history during the month of December, 2023.

Stryker announces 2023 sales surpassed $20 billion

Medtronic

Stocks like Medtronic (MDT), Stryker (SYK) and NVIDIA (NVDA) are likely to benefit from the rising prospects of Generative AI in healthcare.

Generative AI Reshapes Healthcare: 3 Stocks in Limelight

Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter and full year 2023 on Tuesday, January 30, 2024.  A press release will be issued at approximately 4:05pm ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company's fourth quarter and full year 2023, that ended December 31, 2023.

Stryker to announce financial results for its fourth quarter and full year 2023

BellRing Brands Inc

Hershey

WK Kellogg Co

Mondelez

Insulet

Post Holdings

J. M. Smucker

Utz Brands

Zimmer Biomet Hlds

Investors have such high hopes for popular weight-loss medications like Wegovy and Ozempic, the wonder drugs have sent shock waves through the stock market.

Ozempic and other weight-loss drugs' popularity set these stocks up for big gains

Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

News for Stryker Stock (SYK)